Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flucloxacillin is a narrow-spectrum beta-lactam antibiotic of the penicillin class, primarily used to treat infections caused by susceptible Gram-positive bacteria, especially those producing beta-lactamase (penicillinase). It is commonly prescribed for skin and soft tissue infections, bone and joint infections (such as osteomyelitis), ear infections in children, respiratory tract infections, endocarditis, and for surgical prophylaxis against Staphylococcus aureus. Flucloxacillin works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), thereby preventing cross-linking of peptidoglycan chains essential for cell wall strength and integrity. This action leads to bacterial cell lysis and death. It is resistant to degradation by most staphylococcal beta-lactamases due to its isoxazolyl side chain. Flucloxacillin can be administered orally or parenterally (intravenous or intramuscular injection)[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flucloxacillin.